Oxagen Limited
| Oxagen is a drug discovery and development company specializing in inflammation. The biopharmaceutical company is building a novel drug pipeline with a focus on inflammatory and respiratory diseases. Oxagen’s pipeline of novel small molecule drugs is based on targets validated in man. | |
• Show past press releases
• Edit this company
| Contact Information |  | |
Address:
Phone:
Fax:
Web:
Contact:
| 91 Milton Park
Abingdon OX14 4RY
United Kingdom
+44 (0)1235 443300
+44 (0)1235 443301
http://www.oxagen.co.uk
Sue Charles
+44 (0) 20 7457 2020 |
| Company Facts | | |
| Founded: | Jan 1997 | | Founders: | | | CEO: | Sue Charles | | CTO or technical lead: | | | CFO or finance director: | | | Head of Sales: | | | Head of Marketing: | |
| | Stage: | | | Category: | Biotechnology & Healthcare | | Sector: | Biopharmaceuticals | | Employees: | | | Profitability: | | | Funding raised: | Yes | | Funding sought: | | | Seeking Partnerships: | |
| Non-executive Board Members | | |
Dr. David U'Prichard, President, Druid Consulting LLC
Dr. Graham Boulnois, Partner, SV Lifesciences
Prof. John Bell, Regius Chair of medicine, Oxford, Dura Pharmaceuticals Inc.
Dr. Stuart Collinson, Partner, Forward Ventures Fund
Ed Mascioli MD, Venture Partner, MPM Capital
Dr. Luke Evnin, General Partner, MPM Capital
| Key Customers | | |
not disclosed
| Key Business Partners | | |
not disclosed
| Key Competitors | | |
not disclosed
| Capital Raised | | |
To view this information you must be signed in and subscribed to the online dataservice, sign in here.
To read more about the Online data service click here |
| Public Offerings | | |
| Date | Type | Exchange |
| No public offerings |
|
| | Data
27,633
Tech investments
From our Online Data Service
|
17,827
VC-backed companies
From our Radar
|
Recent Deals
For information on Europe's most extensive database on technology funding click here!
|  |
Events
Press Releases
|
